希罗达对食道癌放射治疗增敏的临床研究

目的:探讨希罗达配合放疗对食道癌的临床疗效和毒副反应。方法:选取40例食道癌患者,随机分为2组,各20例,试验组进行放射治疗+希罗达联合治疗;放疗方法两组均用直线加速器6MV-X线三野治疗,5次/周,2Gy/次,区域总剂量60~66Gy/30~33次/6~7周,同步给予希罗达500mg/m2,2次/d,对照组单纯放射治疗。结果:全程治疗后2个月,两组食道病灶及区域淋巴结消退率(CR+PR)分别为60%(12/20)、25%(5/20),差异有显著性(P<0.05);吞咽困难的改善优于对照组(P<0.05);毒副反应与对照组相当(P>0.05)均较轻,未见Ⅲ、Ⅳ级毒副反应。结论:希罗达作为食道癌患者的放疗增敏剂有较好的临床放疗增敏作用,其毒副反应患者可耐受。

Reinforcement Effect of Xeloda for Radiotherapy of Esophagus Cancer

Objective: To investigate the curative effect and toxicity of xeloda combined with radiation therapy on patients with esophagus carcinoma.Methods:40 patients were randomly divided into two groups: RT plus xeloda(RT+X) group and radiotherapy(RT) group.The RT+X group(20 cases) was given xeloda 500mg/m2,twice per day,in the course of RT.The RT(conventional RT) was carried out by linear accelerator(6MV-Xray) to irradiate the esophagus cancer to 60～66Gy/30～33F/6～7W in both groups.Results:The local control rates 2 months after therapy terminated were 60% in RT+X group and 25% in RT group(P<0.05);The swallowing difficulties and the pains of the chest in RT+X group realized improvement.Toxicity in two groups were well tolerated in majority of patients.Conclusion:Xeloda is effective in increasing tumor radiation sensitivity for the patients with esophagus carcinoma and the toxicity is well-tolerated.